Artificial Intelligence-Driven Discovery of Pyrazolo[1,5- a ]pyrimidine Derivatives as Novel Phosphodiesterase 4 Inhibitors for Treating Idiopathic Pulmonary Fibrosis
- 18 November 2025
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (22) , 24436-24455
Abstract
Phosphodiesterase 4 (PDE4) has been validated as a promising therapeutic target for idiopathic pulmonary fibrosis (IPF), a devastating interstitial lung disease lacking really effective therapeutic drugs, particularly exacerbated in the post-COVID-19 era. Herein, we reported the discovery of 13c, a novel pyrazolo[1,5-a]pyrimidine-based PDE4 inhibitor, via an innovative artificial intelligence (AI)-driven virtual screening approach integrated with structure-based design. The cocrystal analysis of PDE4-13c elucidated the structural basis of its high affinity, revealing that the unique "halogen-binding and metal-coordination" synergistic network significantly influenced PDE4 inhibitory activity, which resulted in a 268-fold potency enhancement (IC50 = 2.7 nM) over hit T3700 (IC50 = 725 nM). Notably, 13c exhibited remarkable hepatic microsomal stability (RLM1/2 = 141.4 min). Furthermore, 13c exhibited remarkable antifibrotic activity in vitro and significantly attenuated bleomycin-induced pulmonary fibrosis in vivo, highlighting its potential as a novel PDE4 inhibitor for IPF.Keywords
Funding Information
- National Key Research and Development Program of China (2023YFF1205102)
- Natural Science Foundation of Hainan Province (222RC556, 823CXTD375, 824RC500, 824YXQN420, KJRC2023B10)
- Hainan University (KYQD(ZR)-21031, KYQD(ZR)-21108, KYQD(ZR)-21126, KYQD(ZR)23002, KYQD(ZR)-23003, XTCX2022JKA01)
- National Natural Science Foundation of China (22277019, 22307031, 22367007, 22377023, 22567014, 82373732)
- Excellent Talent Team Project in Hainan Province (HNYT20250004)
This publication has 48 references indexed in Scilit:
- Discovery of highly potent phosphodiesterase-1 inhibitors by a combined-structure free energy perturbation approachActa Pharmaceutica Sinica B, 2024
- Discovery of amentoflavone as a natural PDE4 inhibitor with anti-fibrotic effectsChinese Chemical Letters, 2024
- Discovery of novel phosphodiesterase-1 inhibitors for curing vascular dementia: Suppression of neuroinflammation by blocking NF-κB transcription regulation and activating cAMP/CREB axisActa Pharmaceutica Sinica B, 2022
- Discovery of novel PDE4 inhibitors targeting the M-pocket from natural mangostanin with improved safety for the treatment of Inflammatory Bowel DiseasesEuropean Journal of Medicinal Chemistry, 2022
- Structure-based discovery of orally efficient inhibitors via unique interactions with H-pocket of PDE8 for the treatment of vascular dementiaActa Pharmaceutica Sinica B, 2022
- Discovery of a highly specific 18F-labeled PET ligand for phosphodiesterase 10A enabled by novel spirocyclic iodonium ylide radiofluorinationActa Pharmaceutica Sinica B, 2021
- Free energy perturbation (FEP)-guided scaffold hoppingActa Pharmaceutica Sinica B, 2021
- Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progressEuropean Journal of Medicinal Chemistry, 2021
- Therapeutic targets and potential agents for the treatment of COVID‐19Medicinal Research Reviews, 2021
- The discovery, complex crystal structure, and recognition mechanism of a novel natural PDE4 inhibitor from Selaginella pulvinataBiochemical Pharmacology, 2017